ARTICLE | Company News
Cell Therapeutics receives Trisenox approval
September 26, 2000 7:00 AM UTC
The FDA granted marketing approval to CTIC for its Trisenox arsenic trioxide injection to treat relapsed or refractory acute promyelocytic leukemia (APL). The company submitted the NDA in April. Trise...